WO1998029069A2 - Procede de modification de la refringence d'un oeil - Google Patents

Procede de modification de la refringence d'un oeil Download PDF

Info

Publication number
WO1998029069A2
WO1998029069A2 PCT/US1997/023794 US9723794W WO9829069A2 WO 1998029069 A2 WO1998029069 A2 WO 1998029069A2 US 9723794 W US9723794 W US 9723794W WO 9829069 A2 WO9829069 A2 WO 9829069A2
Authority
WO
WIPO (PCT)
Prior art keywords
changing
refractive power
eye
corneal profile
change
Prior art date
Application number
PCT/US1997/023794
Other languages
English (en)
Other versions
WO1998029069A3 (fr
WO1998029069B1 (fr
Inventor
Michael E. Stern
David F. Power
Janet K. Cheetham
Original Assignee
Allergan Sales, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales, Inc. filed Critical Allergan Sales, Inc.
Priority to AU58059/98A priority Critical patent/AU5805998A/en
Publication of WO1998029069A2 publication Critical patent/WO1998029069A2/fr
Publication of WO1998029069A3 publication Critical patent/WO1998029069A3/fr
Publication of WO1998029069B1 publication Critical patent/WO1998029069B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/013—Instruments for compensation of ocular refraction ; Instruments for use in cornea removal, for reshaping or performing incisions in the cornea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Definitions

  • the present invention generally relates to a method for changing the refractive power of an eye and is more particularly directed to changing the profile of the cornea of an eye to correct refractive disorders.
  • the refractive power of an eye is expressed by the inverse number 1/f of the focal length, f, of the object.
  • myopia and hyperopia result from conditions in which light entering an eye is not exactly focused on the retina.
  • Another condition resulting from improper focusing of light is that of a stigmatism.
  • a stig atism is the result of unequal curvature of the refractive surface of the eye as result of which a ray of light is not sharply focused on the retina but is spread over more or less a diffuse area.
  • the structure of an eye includes an eyeball filled with a vitreous body with the top most
  • ⁇ surface of the eye being a transparent cornea followed by an iris, a pupil and a crystalline lens respectively.
  • Refractive index of the cornea is about 1.38 compared to 1.0 of air and incident light entering the cornea is refracted before being focused on the retina.
  • the crystalline lens is varied in thickness and the focal length thereof is adjusted accordingly.
  • a number of procedures have been utilized to alter the shape, or the profile, of the cornea in order to change its refractive index to correct for the hereinabove noted conditions resulting in improper focusing of an object on the retina of an eye.
  • radial keratoto y utilizes incisions in a radial pattern around an outer periphery of the cornea enabling the periphery to expand slightly and flattened the center of the cornea.
  • Surgical procedures such as lamellar refractive keratoplasty involves the thickening of the cornea by suturing of a material thereto.
  • Another procedures includes the use of lasers for photorefractive keratectomy which shapes anterior layers of the cornea by photoablation.
  • the vaporization of portions of the center of the cornea effectively change the cornea shape as portions of the cornea relax into the oblated areas.
  • Still another procedure such as thermal keratoplasty effects a change in corneal profile by shrinking collagen fibrils in the cornea.
  • trauma associated with the alteration of corneal tissue results in apoptosis, programmed cell death, an active process of a gene-directed physiological event that plays a crucial role in the regulation of tissue homeostasis such as development, maintenance of tissue morphology and cellular reorganization after tissue wounding.
  • the stroma of an eye includes lamellae which run in flat layers from limbus to limbus and consist of uniform, parallel collagen fibrils, which are regularly spaced within the lamellae and separated by the glycoproteins.
  • the uniformity of the collagen fibrils results in the transparency of the cornea and when is this uniformity of size or spacing of the fibrils is disrupted, necessary transmission of light directed into the eye is altered. Naturally, any surgical procedure which results in a disruption or alteration of light entering the eye causes a refractive disorder.
  • alterations such as shrinking preexisting collagen at the cornea treatment site results in a change in refractive index.
  • the biological response hereinabove noted which includes the process of keratocyte reproduction, migration and repopulation results in an addition of new collagen and other compounds to the preexisting stromal configuration over a period of time.
  • the stroma develops a different shape that alters the corneal curvature subsequent to surgery.
  • a regression of the refractive properties of the eye occurs due to this biological response to surgical procedures on the corneal surface. Accordingly, immediate changes to a corneal profile or a curvature are not stable but change as a result of the biological response over a period of time consequent to the corneal trauma.
  • cornea trauma results in a correspondingly greater biological response and accordingly accommodation, or compromise for expected biological response becomes particularly significant when diopter changes of +6 or greater are necessary to achieve emmetropia.
  • the stroma develops a significantly different properties that alter the corneal curvature over a period of time due to biological response.
  • this biological response includes the process of keratocyte reproduction, migration and new population which results in the addition of new collagen to the preexisting scroll configuration over a period of time subsequent to corneal trauma.
  • the present invention is directed to a method for changing the refractor power of an eye by changing the shape of the cornea without concomitant biological response which causes regression of the achieved refractive power due to a change in the corneal profile. This results in more accurate dioptic correction by eliminating the effects of biological response which may not be as be predicable as the calcuulation of necessary diopter change to achieve emmetropia.
  • a method in accordance with the present invention for changing the refractive power of an eye generally includes the steps of selecting a diopter correction for an eye without compromise for regression of refractive power due biological response to a change in corneal profile.
  • the present invention includes a step of changing the corneal profile of the eye in order to change the refractive power of the eye to the select diopter.
  • the present invention includes the step of limiting regression in corneal profile in order to maintain refractive power at about the selected diopter by applying to the cornea a composition comprising an agent for controlling the biological response.
  • the method in accordance with the present invention may incorporate into the step of changing a corneal profile a radial keratotomy procedure.
  • the change of corneal profile may include a photorefractive keratectomy.
  • the change in corneal profile may include a thermal keratoplasty procedure.
  • Greater benefit of the method in accordance with the present invention may be achieved by changing the corneal profile to effect a refractive power change of at least 6 diopters.
  • the method according to the present invention includes a change in a refractive power which causes emmetropia.
  • composition comprising an agent for controlling the biological response to the cornea in anticipation of changing the corneal profile yet after the step of selecting a diopter correction for an eye without compromise regression of refractive power due to biological response to a change in the corneal profile.
  • the present invention further encompasses a method for changing a refractive power of an eye which includes changing the corneal profile of the eye in order to change to change the refractive power of the eye to a selected dioptic and thereafter controlling biological response to the change in corneal profile in order to maintain a refractive power at about the selective diopter by applying to the cornea a composition comprising an agent for limiting the biological response.
  • This control may be effected by either the amount of agent present in the composition or the quantity and time schedule for application of the composition.
  • the present invention includes a method of changing the refractive power of an eye by surgically changing the corneal profile of the eye in order to change the refractive power thereof with a selected diopter and retarding regression of the selected diopter by applying to the cornea a composition comprising an agent for controlling a biological response to the surgical change to the corneal profile.
  • the agent utilized may comprise a steroid, more specifically the steroid may be present in a concentration of about 0.1 to about 4.0 wt. % and may be selected from the group consisting of deramethasone, prednisolone, prednisone, fluorometholone, rimxolone, medrysone, betamethasone, triamcinolone and hydrocortisone.
  • the agent may comprise a non-steroidal antiinflammatory
  • a non-steroidal antiinflammatory may be selected from the group consisting of flurbibrofin, suprofen, mefenamic acid, flufenamic acid, clonixin flufensal, ibufenac 4-(t- butyl) benzeneacetic acid, ibuprofen, alkylofenac, fenoprofen, naproxen, indonmathacin, tolmetin, ketoprofen, namoxyrate, ketrolac, and loxprofen.
  • Figure 1 is a pod illustrating the advantages of a dioptic correction to the present invention for changing corneal profile.
  • the present invention relates to a method for changing refractive power of an eye by changing the curvature of the cornea of an eye to correct for refractive disorders.
  • the present invention is directed to a method for changing corneal curvature which may include radial keratotomy, laser photo refractive keratectomy, thermal keratoplasty as conventionally known and used in combination with a selection of a diopter correction for an eye which does not include compromise for regression of the refractive power due to biological response.
  • a method for changing corneal curvature which may include radial keratotomy, laser photo refractive keratectomy, thermal keratoplasty as conventionally known and used in combination with a selection of a diopter correction for an eye which does not include compromise for regression of the refractive power due to biological response.
  • such regression is limited or eliminated in order to maintain the refractor power at about the selected diopter by applying to the cornea a composition comprising an agent for controlling the biological response.
  • the method in accordance with the present invention encompasses a procedure which limits the destruction, or shrinkage, or change of preexisting collagen and preexisting keratocyte population.
  • the procedure in accordance with the present invention is neither taught or suggested by the prior art.
  • the included step of controlling biological response which includes the process of keratocyte reproduction, migration and repopulation which results in the addition of new collagen and other compounds to the preoperational stroma configuration which occurs subsequent to the change in the corneal profile.
  • an eye having a preexisting diopter -6 indicated as curve A would require a diopter change to, for example, +1 in order to accommodate for the regression over a period of time indicated by the curved segment 10 to achieve an emmitropia, or diopter of 0.
  • the selected change in diopter can be approximately equal to the change necessary to achieve emmetropia without compromise for biological response to the cornea profile.
  • the biological response which may be expected to the profile change of the cornea corresponding to curve B of Figure 1 may amount to 4 or 5 diopters as indicated by the difference between the maximum diopter change indicated by the point 20 in Figure 2 and the stable diopter correction as indicated by the line segment 14 caused by biological change to the corneal trauma.
  • the selected diopter correction for an eye without compromise for regression of refractive power amounts to the difference between the preexisting diopter of the eye and 0 diopter (emmetropia) . That is no compromise is necessary for regression of the diopter due to biological response because such response is controlled by active agents hereinafter described.
  • Suitable active agents include healing modulators such as steroids, growth factors, basement membrane components and regulators of collagen structure.
  • Steroids are known for their role in controlling inflammation and inhibiting wound healing; see, Olsen et al., The Effect of Steroids on the Healing of the Corneal Endothelium, Acta Ophthalmologica, 62, pp. 893- 899 (1984) ; Singh. Corticosteroids in Corneal Endothelial Wound Healing, Annals of Ophthalmology, Vol. 17, no. 4, pp. 238-243 (April, 1985); Woost et al . , Effect of Growth Factors with Dexamethasone on Healing of Rabbit Corneal Stromal Incisions, Exp. Eye Res. 40, pp. 47-60 (1985); Kossendrup et al .
  • steroids which can be used according to the present invention include all steroids which are capable of preventing or controlling biological response resulting from trauma to a cornea.
  • steroids which can be employed in the present invention to prevent and control biological response include dexamethasone; fluorometholone ; medrysone; betamethasone; triamcinolone; prednisone; prednisolone such as prednisolone acetate; hydrocortisone and pharmaceutically acceptable salts thereof; prednicarbate; deflaxacort halomethasone tixocortol; prednylidene (21 diethylaminoacetate; prednival; paramethasone; methylprednisolone; meprednisone; mazipredone; isoflupredone; halopredone acetate; halcinonide; formocortal ; flur
  • steroids are known compounds. Further information regarding the compounds can be found in the Merck Index Tenth Edition, 1983, and the publications cited therein, the entire contents of which are incorporated herein by this specific reference thereto. Additional examples of steroids which can be used according to the present invention include; dexamthasone ether derivatives; alkyloid steroids of the pregnane series (Rimexolone) disclosed generally in U.S. Pat. No. 3,947,478 issued Mar. 30, 1976 and specifically for ophthalmic use in U.S. Pat. No. 4,686,214 issued Aug. 11, 1987, the entire contents of both of which are incorporated herein by this specific reference thereto.
  • Such steroids and combinations comprising one or more steroids will typically be combined in the compositions of the present invention at concentrations of between about 0.1 and 4.0 percent by weight (wt. %) .
  • the following steroids are preferred; dexamethasone; prednisolone and fluoromethalone.
  • the preferred steroids can be used at concentrations between about 0.125 and 1.0 wt. %.
  • Growth factors are also agents useful in accordance with the present invention which cause cells to migrate, differentiate, transform or mature and divide. They are polypeptides which can usually be isolated from many different normal and malignant mammalian cell types. Some growth factors can be produced by genetically engineered microorganisms, such as bacteria (E. coli) and yeasts; see, for example, Chapter 10 and 11 of the Molecular and Cellular Biology of Wound Repair (1986) , the entire contents of the book of which are incorporated in the present specification by this specific reference thereto. Growth factors are known for their involvement in a variety of phenomena as set forth above. For example, epidermal growth factor (ECF) is known to stimulate the proliferation of epidermal and other epithelial tissues; see Barrandon et al., Cell. Vol.
  • ECF epidermal growth factor
  • ECF ECF
  • TGF transforming growth factor
  • European Patent No. 190 018 disclosing the use of TGF for the treatment of epithelial and stromal wounds
  • PCT WO 86/02271 disclosing the use of human epidermal growth factor (hEGF) for treating epithelia and stromal wounds
  • European Patent No. 140 998 disclosing ophthalmic preparations containing hEGF for the treatment of keratitis, corneal erosion, corneal infiltration and corneal ulcers
  • Growth factors which can be used according to the present invention include EGF, fibroblast growth factor (FGF, insulin-like growth factor (IGF) , platelet derived growth factor (PDGF) , alpha and beta transforming growth factors (TGFA and TGFB) and nerve growth factor (NGF) .
  • FGF fibroblast growth factor
  • IGF insulin-like growth factor
  • PDGF platelet derived growth factor
  • TGFA and TGFB alpha and beta transforming growth factors
  • NGF nerve growth factor
  • cell enhancing solutions which contain growth factors can be used, such as SGF-7, available from Scott Laboratories, Inc., and ITS, available from Collaborative Research Incorporated. Growth factors will typically be contained in the compositions of the present invention at concentrations between about 0.01 nanograms per milliliter (ng/ml) and 100 micrograms per milliliter ( ⁇ g/ml) .
  • EGF can be used at concentrations between about 500 ng/ml and 100 ⁇ g/ml, preferably between about 10 ⁇ g/ml and 50 ⁇ g/ml; and FGP can be used from between about 1.0 ng/ml and 50 ⁇ g/ml, preferably at about 10 ⁇ g/ml.
  • TGF ⁇ can be used at concentrations of at least about 100 ng/ml; see Lawrence et al., Annal. Surg. 203, pp. 142-147 (1986).
  • Basement membrane components can be used to prevent or control collagen changes in the biological response. It has been theorized that basement membrane components promote wound healing by contributing to the reformation of destroyed basement membranes or functioning as a basement membrane, thereby providing a surface across which epithelial cells can migrate and allowing re-epithelialization of the cornea to progress; see Fajikawa, et al., Fibronectin in Healing Rabbit Corneal Wounds, Laboratory Investigation, Vol. 45, No. 2, pp. 120-8(1981) incorporated herein by reference.
  • Basement membranes are thin amorphous, sheet-like structures which separate certain parenchymal cell types, endothelium and epithelium, from connective tissue stroma. For a discussion of basement membranes and their role in wound repair; see The Molecular and Cellular Biology of Wound Repair, Chapter 22, specifically p. 550 (1986).
  • basement membrane components are employed to control corneal epithelial cells in division, migration and sticking. They influence endothelial cells by providing an attachment and organizational foundation for the endothelial cells. They also help with the organization of collagen in the stroma.
  • Basement membrane components which can be used to control biological response include: heparin; heparin sulfate; fibronectin; laminin; connective tissue activating peptides such as vinculin; gelatin; glycosaminoglycans; and various types of collagen, especially type IV collagen.
  • the present compositions will typically contain one or more basement membrane components at concentrations between about 0.01 ng/ml and 1 milligram per milliliter (mg/ml) , preferably about 1 ⁇ g/ml.
  • Regulators of collagen structure can also be used as wound healing modulators to control biological response and regulate collagen structure.
  • regulators of collagen structure are wound healing modulators which degrade or inhibit the breakdown of collagen in the stroma or the collagen released by dead or injured cells; see The Molecular and Cellular Biology of Wound Repair; at pp. 224-226. These regulators can act in two ways, to degrade damaged connective tissue, such as collagen at inflammatory sites, or to act in the reverse manner inhibiting the degradation of connective tissue.
  • Regulators of collagen structure which can be used to degrade collagen include, for example: collagenases, elastases, proteases and proline hydroxelase.
  • Regulators of collagen structure which will inhibit the degradation of collagen include all known inhibitors of the aforementioned enzymes including phenylmethylsulfonyl fluoride (PMSF) and pyrridine- dicarboxylic acid esters used as proline hydroxylase inhibitors, fibrosuppressants and immunosuppressants as disclosed in U.S. Pat. No. 4,717,727, the contents of which are hereby incorporated by this specific reference in this specification. Regulators of collagen structure can be used at concentrations of between about 10 ⁇ g/ml to about 10 g/ml.
  • PMSF phenylmethylsulfonyl fluoride
  • pyrridine- dicarboxylic acid esters used as proline hydroxylase inhibitors
  • fibrosuppressants and immunosuppressants as disclosed in U.S. Pat. No. 4,717,727, the contents of which are hereby incorporated by this specific reference in this specification.
  • Regulators of collagen structure can be used at concentrations of between about
  • compositions herein described Prior to, or during, photoablation or other surgical change in profile of the anterior surface of the cornea the compositions herein described may be applied.
  • Such compositions include growth factors such as EGF, IGF, PDGF, FGF, TGF ⁇ , TGF ⁇ and NGF and basement membrane components.
  • aldose reductase inhibitors can be used as wound healing modulators according to the present invention.
  • ARIs such as those disclosed in U.S. Pat. Nos. 4,717,725, 4,600,717, 4,436,745, and 4,438,272, the entire contents of which are incorporated herein by this specific reference, can be used to central biological response.
  • These compounds inhibit the enzyme aldose reductase.
  • the enzyme's inhibition appears to be related to the mechanism of wound healing in the diabetic individual; see Ohasti et al., Aldose Reductase Inhibitor (CT-112) Eyedrops for Diabetic Corneal Epitheliopathy, Americal Journal of Ophthalmology, Vol. 105, No. 3 (March, 1988) .
  • ARIs can be used at concentrations between about 0.1 wt . % and 2.0 wt . % .
  • EGF EGF
  • FGF FGF
  • IGF IGF
  • PDGF PDGF
  • TGF ⁇ TGF ⁇
  • NGF aldose reductase inhibitors
  • nonsteroidal antiinflammatory agents can be used to control biological response resulting from UV photoablation.
  • Nonsteroidal antiinflammatory agents which can be used according to the present invention will typically comprise; loxoprofen, as disclosed in British Patent No. GB 2,144,993A, published Mar. 12, 1985, incorporated herein by reference. Compounds disclosed in U.S. Patent No. 4,559,343, issued Dec. 17, 1985 and incorporated herein by this specific reference can also be used.
  • Those compounds include: flubiprofen; suprofen; aryl or heteroarylcarboxylic acids such as mefenamic acid, flufenamic acid, clonixin, flufensial; aryl or heteroarylalkynoic acids such as 4-(t-butyl) benzeneacetic acid, ibufenac, ibuprofen, alkylofenac, fenoprofen, naproxen, indomethacin, tolmetin, ketoprofen and namoxyrate.
  • ketorolac, or pyrrolo pyrroles disclosed in U.S. Pat. No. 4,454,151 issued June 12, 1984 and incorporated herein by reference, can be used.
  • Such NSAIs can be used at concentrations of between about 0.1 and 2.0 wt. %.
  • Preferred NSAIs include: suprofen, loxoprofen, flurbiprofen, iodomethacin and ketorolac. These compounds are typically present in the compositions at the following concentrations; suprofen at about 1.0 wt. %, loxoprofen at about 1.0 wt. %, flurbiprofen at about 0.25 wt. %, indomethacin from about 0.1 to 1.0 wt. % and ketorolac at about 0.5 to 1.0 wt. %.
  • Anti-oxidants can also be used to control biological response resulting from photoablation of the cornea.
  • tissue such as the cornea
  • trauma for example UV radiation
  • reactive species in excess of those normal present as a result of enzymatic and nonenzymatic reactions are produced.
  • reactive species including free radicals, can cause tissue damage; see The Molecular and Cellular Biology of Wound Repair, specifically Chapts 1, 6 and 7; and Fisher, Intracellular Production of Oxygen Radicals and Tissue Injury, Proceedings of a Book Lodge Symposium (April 1987) , which is incorporated herein by this specific reference.
  • Anti-oxidants prevent scar formation and control biological response by scavenging free radicals. Suitable anti-oxidants include, for example; ascorbic acid; glutathione; see Meister, Selective Modification of Glutathione Metabolism, Science, Vol.
  • anti-oxidants can be used at concentrations between about 0.001 ng/ml and 1 mg/ml, preferably about 100 ng/ml.
  • Immunomodulators can also be used to control biological response.
  • Immunomodulators which may be used include: cyclosporin A and cyclosporin G, leflunomide, N- (4-trifluoromethylphenyl) -N-(2-cyano-l- hydroxy-1-propen-l-yl) carboxamide and interferon (y, ⁇ and ⁇ ) .
  • Immunomodulators can be used at concentrations between about 2 and 10 wt. %.
  • Antiallergics are wound healing modulators which can also be used to control biological responses resulting from trauma to the cornea.
  • This class of compounds includes for example: cyproheptadine, dipheniramine, azelastine, cimetidine, neodocromil, cromolyn, lodoxamide, pheniramine and 6-methyl-N-(lH- tetrazol-5 yl) -z-pyridinecarboxamide.
  • Such antiallergic compounds can be used at concentrations of about 0.1 to 4.0 wt. %.
  • Wound healing modulators which can be used to control biological response, insulin like growth factor (IGF) and insulin; and tumor necrosis factor (TNF) .
  • IGF insulin like growth factor
  • TNF tumor necrosis factor
  • Such growth factors can be used in accordance with the foregoing discussion of this class of wound healing modulators.
  • the immunomodulators, antiallergics and basement membrane components, as previously set forth, can be used in this situation.
  • Antimicrobials can be used according to the present invention pre-operatively and post-operative thereby safeguarding against corneal infection which inhibits healing, possibly leading to corneal edema and the formation of corneal haze.
  • Antimicrobials which can be used according to the present invention include: chloramphenicol , erythromycin, gentamycin, polymyxin, sulfacetamide, tetracycline, tobramyin, sulfisoxazole, diolamine, ciprofloxacin, natamycin, neomycin, ofloxacin, norfloxacin, trifluorothymidine, acyclovir, gancy-clovir, vancomycin and other antibacterial, antiviral and antifungal agents.
  • the compositions comprise one or more antimicrobials or combinations of antimicrobials and other wound healing modulators. Such antimicrobials are used at concentrations between about 0.05 and 3.0 wt. % preferably less than about 1.0 wt. %.
  • compositions of the present invention can be applied alone or in combination with other agents to control biological response.
  • individual agents or combinations thereof can be applied uniquely or sequentially. While the effective dose and treatment regime are left to the discretion of the clinician, the following procedures are recommended.
  • compositions which can be used to control biological response are formulated in compositions for topical application to the eye.
  • the compositions can be formulated in various pharmaceutically acceptable forms for topical ophthalmic delivery including; solutions, suspensions, emulsions, gels and solid inserts, depending on the nature and characteristics of the agents.
  • Preferred formulations are aqueous solutions.
  • agents of the present invention can be applied via the use of a collagen shield, contact lens or other solid matrix placed on the ocular surface. Such shields, lenses or matrices can provide for slow release of the modulators as well as serving as a protective environmental barrier.
  • compositions of the present invention may further comprise various formulatory ingredients, such as antimicrobial preservatives and tonicity agents.
  • antimicrobial preservatives include; benzalkonium chloride, thimerosal, chlorobutanol, methylparaben, propylparaben, phenylethyl alcohol, EDTA, sorbic acid, POLYQUAD and other agents equally well known to those skilled in the art.
  • Such preservatives, if employed, will typically be used in an amount from about 0.0001 wt. % to 1.0 wt. %.
  • Suitable agents which may be used to adjust tonicity or osmolality of the compositions include: sodium chloride, potassium chloride, mannitol, dextrose glycerine and propylene glycol. If used, such agents will be employed in an amount of about 0.1 wt.% to 0.0 wt.%. However, preferable compositions of the present invention will not include preservatives of tonicity agents which are known to adversely affect or irritate the eye, particularly the cornea.
  • the administration, sequence of administration when more than one composition is used, and the concentrations of the wound healing modulators used depends on numerous factors. These factors can include; the specific agents being used, the nature of the surgical procedure, and various clinical factors, including the extent and type of dioptic change, the medical history of the patient, symptoms apparent prior to, during, or after surgery, such as inflammation or edema, etc. Selection of specific agents or combinations thereof, their concentrations and sequence of delivery to the eye will be made by the skilled clinician guided by the foregoing description.
  • amalgamates compounds, or compositions, collectively referred to herein as "adjuncts" which can be used alone, or in addition to the agents discussed above, that contribute to the overall health and comfort of the eye, thus contributing to its treatment.
  • Adjuncts for controlling intraocular pressure which can be used in combination with agents of the present invention, include antihypertensive agents.
  • Antihypertensive agents which can be used include, for example, timolol, betaxolol, levobunalol, glycerin, isosorbide, manitol, urea, paraminoclonidines, epinephrine and carbonic anhydrase inhibitors.
  • the compounds can be topically applied to the eye following photoablation at concentrations between about 0.1 and 2.0 wt.
  • miotics can be used to control intraocular pressure.
  • miotics such as carbachol, pilocarpine, physostigmine, echothiophate and isofluorphate can be used.
  • Humectants may be used prior to, during and after photoablation of the cornea. These adjuncts promote healing of the cornea by providing lubrication and preserving the natural tear physiology.
  • Humectants can include preparations which typically comprise hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethy1cellulose, methylcellulose, polyvinyl alcohol, cellulose esters, povidone or other suitable polymeric systems.
  • Epithelial cell health promoters as used herein, are compounds known to contribute to the health of the epithelial cells of the cornea. The presence of these compounds prior to, during, and/or after photoablation of the cornea can encourage the rapid resumption of epithelial integrity and prevention of stromal edema.
  • Epithelial cell health promoters which can be used as adjuncts to the agents of the present invention include: ascorbic acid; retinoids, such as retinoic acid, retinol, retinal and retinoyl B-glucuronide; aloe vera; collagenase inhibitors; prostaglandins, such as prostaglandin E 2 and elastase inhibitors.
  • the present invention also encompasses methods of treatment of an eye exposed to laser radiation during ophthalmic procedures, particularly UV radiation.
  • Methods of treatment, during ophthalmic surgery, with compositions containing agents disclosed above include application of the compositions before laser exposure, during the procedures, for example when the ye is moistened and a wet keratoscope reading is taken during corneal sculpting using a UV laser and/or immediately after irridation.
  • the compositions of the present invention can be applied uniquely or when the use of more than one agent is indicated, the medicaments can be administered sequentially.
  • the following formulation is an example of a wound healing modulator composition that can be used for the prevention and treatment of corneal haze resulting from laser irradiation. It is not limiting but considered representative of useful compositions of the present invention.
  • compositions can be formulated by mixing the specific components at the indicated concentrations.
  • the compositions should be either prepared under sterile conditions or sterilized after their preparation and prior to use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Procédé pour la modification de la réfringence d'un oeil, consistant à choisir une correction dioptrique pour un oeil, sans compromis lié à la baisse de réfringence due à une réaction biologique découlant d'un changement du profil cornéen, puis à modifier le profil de la cornée de l'oeil considéré pour amener la réfringence de cet oeil à la dioptrie voulue (par exemple, au laser ou sur intervention chirurgicale) et, enfin, à limiter la régression du profil cornéen (due aux réactions biologiques parasites) environ à la dioptrie retenue en appliquant à la cornée une composition renfermant un agent capable de maîtriser la réaction biologique. L'agent peut être un anti-inflammatoire stéroïde ou non stéroïde ou bien un constituant de la membrane basale. L'objectif de la modification de réfringence est d'induire l'emmétropie. Le procédé décrit permet de corriger les troubles de réfringence/d'accommodation, comme la myopie, l'hyperopie, l'(a)stigmatisme, etc.
PCT/US1997/023794 1997-01-02 1997-12-29 Procede de modification de la refringence d'un oeil WO1998029069A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU58059/98A AU5805998A (en) 1997-01-02 1997-12-29 Method for changing the refractive power of an eye

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77803297A 1997-01-02 1997-01-02
US08/778,032 1997-01-02

Publications (3)

Publication Number Publication Date
WO1998029069A2 true WO1998029069A2 (fr) 1998-07-09
WO1998029069A3 WO1998029069A3 (fr) 1998-10-08
WO1998029069B1 WO1998029069B1 (fr) 1998-11-12

Family

ID=25112096

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/023794 WO1998029069A2 (fr) 1997-01-02 1997-12-29 Procede de modification de la refringence d'un oeil

Country Status (2)

Country Link
AU (1) AU5805998A (fr)
WO (1) WO1998029069A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095913A1 (fr) * 2000-06-13 2001-12-20 Synphora Ab Procedes et compositions destines a la prevention de la myopie
US6878694B2 (en) 2000-12-20 2005-04-12 Alcon, Inc. Ophthalmic irrigating solution adapted for use in lasik surgery
US6919321B2 (en) 2000-12-20 2005-07-19 Alcon, Inc. Ophthalmic lubricating solution adapted for use in lasik surgery
WO2008070848A2 (fr) * 2006-12-07 2008-06-12 Priavision, Inc. Procédé et matériau d'augmentation de la structure cornéenne in situ

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3831604A (en) * 1973-04-18 1974-08-27 C Neefe Method of reshaping the cornea
CA1016435A (fr) * 1973-06-28 1977-08-30 Charles W. Neefe Moule concave permettant de reformer la cornee et d'eliminer toute mauvaise refraction
WO1989004172A1 (fr) * 1987-11-09 1989-05-18 Chiron Ophthalmics Inc. Procede et composition de cicatrisation de blessures
EP0364266A2 (fr) * 1988-10-12 1990-04-18 Eye Research Institute Of Retina Foundation Inc NSAID et/ou EGF pour augmenter la guérison des blessures de l'endothélium de la cornée
US4973466A (en) * 1988-06-21 1990-11-27 Chiron Ophthalmics, Inc. Wound-healing dressings and methods
US4983580A (en) * 1986-04-04 1991-01-08 Allergan, Inc. Methods and materials for use in corneal wound healing
WO1993006856A1 (fr) * 1991-10-11 1993-04-15 Mark Cedric Gillies Traitement des fibroses ophtalmiques par l'interferon alpha
WO1993007840A1 (fr) * 1991-10-15 1993-04-29 Advanced Corneal Systems, Inc. Orthokeratologie enzymatique
WO1994005322A1 (fr) * 1992-09-04 1994-03-17 Summit Technology, Inc. Agent reducteur de l'activite des plasmines pour le traitement d'une plaie resultant de l'ablation superficielle de la cornee et procede de depistage associe
US5401510A (en) * 1988-10-03 1995-03-28 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
WO1995020969A1 (fr) * 1994-02-04 1995-08-10 University Of Southern California Procede de prevention de la perte de keratocytes

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3831604A (en) * 1973-04-18 1974-08-27 C Neefe Method of reshaping the cornea
CA1016435A (fr) * 1973-06-28 1977-08-30 Charles W. Neefe Moule concave permettant de reformer la cornee et d'eliminer toute mauvaise refraction
US4983580A (en) * 1986-04-04 1991-01-08 Allergan, Inc. Methods and materials for use in corneal wound healing
WO1989004172A1 (fr) * 1987-11-09 1989-05-18 Chiron Ophthalmics Inc. Procede et composition de cicatrisation de blessures
US4973466A (en) * 1988-06-21 1990-11-27 Chiron Ophthalmics, Inc. Wound-healing dressings and methods
US5401510A (en) * 1988-10-03 1995-03-28 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
EP0364266A2 (fr) * 1988-10-12 1990-04-18 Eye Research Institute Of Retina Foundation Inc NSAID et/ou EGF pour augmenter la guérison des blessures de l'endothélium de la cornée
WO1993006856A1 (fr) * 1991-10-11 1993-04-15 Mark Cedric Gillies Traitement des fibroses ophtalmiques par l'interferon alpha
WO1993007840A1 (fr) * 1991-10-15 1993-04-29 Advanced Corneal Systems, Inc. Orthokeratologie enzymatique
WO1994005322A1 (fr) * 1992-09-04 1994-03-17 Summit Technology, Inc. Agent reducteur de l'activite des plasmines pour le traitement d'une plaie resultant de l'ablation superficielle de la cornee et procede de depistage associe
WO1995020969A1 (fr) * 1994-02-04 1995-08-10 University Of Southern California Procede de prevention de la perte de keratocytes

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
ARSHINOFF ET AL.: "Use of topical nonsteroidal anti-inflammatory drugs in excimer laser photorefractive keratectomy" J. CATARCT. REFRACT. SURG., vol. 20, no. sup, March 1994, pages 216-222, XP002068878 *
BAEK ET AL.: "Short-term effects of flurbiprofen and diclofenac on refractive outcome and corneal haze after photorefractive keratectomy" J. CATARCT. REFRACT. SURG., vol. 23, no. 9, November 1997, pages 1317-1323, XP002068889 *
BAEK: "The effect of topical corticosteroids on refractive outcome and corneal haze after photorefractive keratectomy" J. REFRACT. SURG., vol. 13, no. 7, November 1997, pages 644-652, XP002068890 *
BRANCATO ET AL.: "Corticosteroids vs diclofenac in the treatment of delayed regression after myopic photorefractive keratectomy" REFRACT. CORNEAL SURG., vol. 9, no. 5, September 1993 - October 1993, pages 376-378, XP002068872 *
CARONES ET AL.: "Efficacy of corticosteroids in reversing regression after myopic photorefractive keratectomy" REFRACT. CORNEAL SURG., vol. 9, no. 2sup, March 1993, pages s52-s56, XP002068874 *
CERRUTI: "The efficacy of topical corticosteroids in reversing the regression of refractive effect after myopic photorefractive keratectomy (PRK)" INVEST. OPHTHALMOL. VIS. SCI., vol. 35, no. 4, May 1994, page 2019 XP002068883 *
COLLIAC: "Photorefractive keratectomy for the correction of myopia and astigmatism" AM. J. OPHTHALMOL., vol. 117, no. 3, 15 March 1994, pages 369-380, XP002068887 *
EPSTEIN ET AL.: "Twenty-four-month follow-up of excimer laser photorefractive keratectomy for myopia" OPHTHALMOLOGY, vol. 101, no. 9, April 1994, pages 1558-1563, XP002068876 *
FAGERHOLM ET AL.: "Effect of postoperative steroids on the refractive outcome of photorefractive keratectomy for myopia with the Summit excimer laser" J. CATARACT REFRACT. SURG., vol. 20, no. sup, March 1994, pages 212-215, XP002068879 *
FERRARI: "Postoperative care in PRK with nonsteroid antiinflammatory drugs (NSAID): a 18 month follow-up clinical study" INVEST. OHPTHALMOL. VIS. SCI., vol. 35, no. 4, May 1994, page 2018 XP002068882 *
FITZSIMMONS ET AL.: "Steroid treatment of myopic regression: acute refractive and topographic changes in excimer photorefractive keratectomy patients" CORNEA, vol. 12, no. 4, July 1993, pages 358-361, XP002068884 *
GOGGIN ET AL.: "Regression after photrefractive keratectomy for myopia" J. CATARACT. REFRACT. SURG., vol. 22, no. 2, March 1996, pages 194-196, XP002068873 *
HAMBERG-NYSTR\M: "Photorefractive keratectomy for low myopia at 5 mm treatment diameter" ACTA OPHTHALMOL., vol. 72, no. 4, August 1994, pages 453-456, XP002068886 *
MARQUES ET AL.: "Corticosteroids for reversal of myopic regression after photorefractive keratectomy" J. REFRACT. SURG., vol. 11, no. 3sup, May 1995, pages s302-s308, XP002068877 *
NASSARALLA ET AL.: "Prevention of keratocyte loss afetr corneal deepithelialization in rabbits" ARCH. OPHTHAMOL., vol. 113, no. 4, 1995, pages 506-511, XP002068888 *
OBRART ET AL.: "The effects of topical corticosteroids and plasmin inhibitors on refractive outcome, haze, and visual performance after photorefractive keratectomy" OPHTHALMOLOGY, vol. 101, no. 9, September 1994, pages 1565-1574, XP002068880 *
SCHIPPER: "Corticosteroid treatment of regression after photorefractive keratectomy for myopia" J. REFRACT. CORNEAL SURG., vol. 10, no. 6, 1994, page 659 XP002068881 *
THOMPSON: "Synthetic epikeratoplasty in Rhesus monkeys with human type IV collagen" CORNEA, vol. 12, no. 1, January 1993, pages 35-45, XP002068885 *
WANG ET AL.: "An empirical model of hyperopic shift with corticosteroid modulation and refractive power prediction after photorefractive keratectomy" J. REFRACT. SURG., vol. 11, no. 3sup, May 1985, pages s314-s318, XP002068875 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095913A1 (fr) * 2000-06-13 2001-12-20 Synphora Ab Procedes et compositions destines a la prevention de la myopie
US6878694B2 (en) 2000-12-20 2005-04-12 Alcon, Inc. Ophthalmic irrigating solution adapted for use in lasik surgery
US6919321B2 (en) 2000-12-20 2005-07-19 Alcon, Inc. Ophthalmic lubricating solution adapted for use in lasik surgery
WO2008070848A2 (fr) * 2006-12-07 2008-06-12 Priavision, Inc. Procédé et matériau d'augmentation de la structure cornéenne in situ
WO2008070848A3 (fr) * 2006-12-07 2008-08-07 Priavision Inc Procédé et matériau d'augmentation de la structure cornéenne in situ

Also Published As

Publication number Publication date
WO1998029069A3 (fr) 1998-10-08
AU5805998A (en) 1998-07-31

Similar Documents

Publication Publication Date Title
US5580570A (en) Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
US4939135A (en) Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation
US5124392A (en) Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation
US5624893A (en) Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
Fagerholm Wound healing after photorefractive keratectomy
Foster et al. Penetrating keratoplasty for herpes simplex keratitis
Van Buskirk Cysts of Tenon's capsule following filtration surgery
Hsu et al. Tissue bioengineering for surgical bleb defects: an animal study
Phillips et al. Effects of prednisolone and medroxyprogesterone on corneal wound healing, ulceration, and neovascularization
Holland et al. Immunohistologic findings and results of treatment with cyclosporine in ligneous conjunctivitis
Phan et al. Topical fibronectin in the treatment of persistent corneal epithelial defects and trophic ulcers
US5271939A (en) Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation
Lee et al. The effect of adjunctive mitomycin C in Molteno implant surgery
Yamaguchi et al. Bullous keratopathy after anterior-posterior radial keratotomy for myopia and myopic astigmatism
Turaçli et al. Topical cyclosporine as a possible new antimetabolite in trabeculectomy
Carter et al. Acute hydrops in pellucid marginal corneal degeneration
WO1998029069A2 (fr) Procede de modification de la refringence d'un oeil
David et al. Corneal wound healing modulation using basic fibroblast growth factor after excimer laser photorefractive keratectomy
JPH10158171A (ja) ビタミンｄ化合物を配合した眼内投与剤
Lahners et al. Keratolysis following excimer laser phototherapeutic keratectomy in a patient with keratoconus
Miller et al. Lack of beneficial effect of intensive topical steroids and beta irradiation of eyes undergoing repeat trabeculectomy
Herschler Long-term results of trabeculectomy with collagen sponge implant containing low-dose antimetabolite
JPH08503968A (ja) 増殖因子と代謝拮抗物質を含有する組成物
Gillies et al. Topical interferon alpha 2b for corneal haze after excimer laser photorefractive keratectomy
Baek et al. Short-term effects of flurbiprofen and diclofenac on refractive outcome and corneal haze after photorefractive keratectomy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP KR

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN JP KR

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase